Skip to main content

Vigabatrin Dosage

Medically reviewed by Drugs.com. Last updated on Sep 3, 2024.

Applies to the following strengths: 500 mg; 100 mg/mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Epilepsy

Initial dose: 500 mg orally twice a day

Maintenance dose: 1500 mg orally twice a day

Comments:

Use: As an adjunct for refractory complex partial seizures in patients who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.

Usual Pediatric Dose for Infantile Spasms

1 month to 2 years of age:
Initial dose: 25 mg/kg orally twice daily

Maximum dose: 150 mg/kg/day in 2 divided doses (75 mg/kg twice daily)

Comments:

Use:

Usual Pediatric Dose for Epilepsy

10 to 16 years; weight 25 to 60 kg:
Initial dose: 250 mg orally twice a day

Maintenance dose: 1000 mg orally twice a day

10 to 16 years; weight greater than 60 kg and patients 17 years or older:
Initial dose: 500 mg orally twice a day
Maintenance dose: 1500 mg orally twice a day

Comments:

Use: As an adjunct for refractory complex partial seizures in patients who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.

Renal Dose Adjustments

Infants with renal impairment: Data not available

10 years of age and older:

Liver Dose Adjustments

Data not available

Dose Adjustments

Elderly: Dose selection should be cautious; renal function monitoring should be considered

Plasma concentration monitoring to optimize therapy is not recommended

Drug Discontinuation:


Drug Withdrawal:
As with all antiepileptic drugs, this drug should be withdrawn gradually, the following recommendations are based on clinical trials:

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for Vigabatrin. It includes elements to assure safe use and an implementation system. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNING: PERMANENT VISION LOSS:


CONTRAINDICATIONS:


Consult WARNINGS section for additional precautions.

Dialysis

Data not available; isolated reports in patients with renal failure on hemodialysis have shown a 40% to 60% reduction in vigabatrin plasma concentrations

Other Comments

Administration advice:


Reconstitution/preparation techniques:
Oral Solution:

General:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.